

Joe Sandys

Special Counsel



jsandys@cooley.com

+44 (0) 20 7556 4237

London

Life Sciences

Emerging Companies

Mergers and Acquisitions

Intellectual Property

Medtech

Venture Capital

Joe's practice focuses primarily on the life sciences sector, advising pharmaceutical, biotechnology and medical technology companies in a wide range of domestic and international intellectual property-based transactions.

He has particular experience in representing life sciences and technology companies in licensing and merger and acquisition transactions, together with the associated operational intellectual property, regulatory and supply chain issues

Notable experience includes advising:

- **Silence Therapeutics** on its \$1.3 billion collaboration with Hansoh Pharma to develop therapeutics Leveraging Silence's mRNAi GOLD™ Platform
- **Silence Therapeutics** on a strategic collaboration with AstraZeneca to discover, develop and commercialise small interfering RNA therapeutics for the treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases
- **Artios**, a leading independent DDR company developing novel cancer therapies, on its collaboration with Merck that will see the latter opt into exclusive development and commercialization of compounds on up to 8 targets
- **Bavarian Nordic** on its €955 million acquisition of the manufacturing and global rights to two commercial vaccines - Rabipur/RabAvert and Encepur – from GlaxoSmithKline
- **Hummingbird Bioscience** on the development of a COVID-19 response program to initiate a clinical trial to study the safety and efficacy of its experimental SARS-CoV-2 antibody therapy, HMBD-115
- **Coalition for Epidemic Preparedness Innovations (CEPI)** on a number of funding agreements, including with Themis Bioscience for the development of a vaccine against Chikungunya and with Oxford University and Janssen Vaccines for the development of adenoviral vectored vaccines against MERS, Nipah and Lassa
- **Immedica Pharma** on its license and supply agreement for pegzilarginase, which is being investigated as a treatment for Arginase 1 Deficiency.
- **Medivir AB** on its exclusive out-license to IGM Biosciences of birinapant, a clinical-stage SMAC mimetic
- **Syneos Health**, the only fully integrated biopharmaceutical solutions organisation, on the acquisition of Illingworth Research Group, a leading provider of clinical research home health services

Education

Oxford University
Postgraduate Diploma (Intellectual Property), 2020,

The University of Law
GDL, LPC, 2011,

University of Sheffield
BA, 2009,

Admissions & Credentials

England and Wales